Lab-Based Services Overview
EpiVax Lab Based Services
EpiVax offers an array of in vitro, ex vivo and in vivo immunogenicity screening services including: cell-free HLA binding assays, a variety of ex vivo immunogenicity assays and in vivo immunogenicity screening in HLA transgenic mice. Our laboratory regularly performs these assays and they are often used to validate our in silico assessments (PreDeFT reports).
At EpiVax we use MHC binding assays to validate the predictions made by the EpiMatrix System. Our binding assays utilize recombinant, soluble MHC molecules and time-resolved fluorescence for the highest sensitivity and the lowest background available on the market. We can perform HLA binding assays for the most common Class II alleles.
We are experienced with many cell-based assays including those based on ELISA and ELISpot technologies. These assays are particularly useful for monitoring T cell activation and proliferation. Cell-mediated and antibody-directed cytotoxicity assays can be used to assess the function of epitopes, vaccine constructs, and therapeutic proteins, including monoclonal antibodies.
Please explore the tabs to the left to learn more about our immunogenicity testing services.
Email Us Here for a PDF brochure describing our Lab-Based Services and/or a Cost Estimate for your project.
T cell response drives B cell response – in this example we show how B cell response to influenza is dependent upon T cell response to antibodies against the HA molecule.
We are dedicated to applying our tools (in-silico, in-vitro and in-vivo) to re-engineering therapeutic proteins and to designing new vaccines. For a recent interview highlighting our CEO’s latest ideas, click on the video: